Custom Services order now ship next day

Utomilumab Overview

Introduction of Utomilumab

Utomilumab is the proposed non-proprietary name for PF-05082566, an investigational immunotherapy and a fully human IgG2 agonist monoclonal antibody (mAb) that binds to the extracellular domain of human 4-1BB/CD137 with high affinity and specificity. It is developed by Pfizer to treat advanced cancers either alone or in combination with other therapies. When utomilumab is injected into a person's bloodstream, it binds to 4-1BB on immune cells and stimulates them. At present, the approval of the monoclonal antibody has not been disclosed in the relevant authoritative drug approval agency, such as the European Medicines Agency and the U.S. Food and Drug Administration (FDA).

Mechanism of Action of Utomilumab

4-1BB/CD137 is an inducible, costimulatory receptor of the tumor necrosis factor (TNF) receptor superfamily expressed on activated immune cells, including effector and regulatory T cells, natural killer (NK) cells, and dendritic cells (DCs). Upon activation, 4-1BB/CD137 signals intracellularly through nuclear factor (NF)-κB and the MAPK cascade, promoting cell proliferation, survival, and cytokine production. Preclinical studies in animal models have demonstrated that agonistic engagement of the immune costimulatory molecule 4-1BB/CD137 leads to enhanced activity of cytotoxic T and NK cells, with effective antitumor responses. In vitro, utomilumab induces NF-κB activation and downstream cytokine production in cell lines and primary lymphocytes. It is capable to block the interaction of 4-1BB/CD137 with 4-1BB ligand (4-1BBL) found mainly on DCs, possibly eliminating reverse signaling through cross-linking 4-1BB/4-1BBL complexes. Furthermore, utomilumab, unlike other CD137 agonist mAbs, is a human IgG2 which requires secondary crosslinking to achieve agonism in vitro. The combination of endogenous ligand blocking and requirement for some degree of cross-linking in situ may enable the delivery of an agonist signal with lower risk of hepatotoxicity. In vivo, utomilumab demonstrated the ability to induce human leukocyte proliferation and to mediate significant antitumor activity, with inhibition of tumor growth in human peripheral blood lymphocyte (PBL)-SCID xenograft models as a single agent.

Mechanism of action of Utomilumab Fig.1 Mechanism of action of Utomilumab

Table 1. Clinical Projects of Utomilumab*

NCT ID Status Conditions Lead Sponsor Update Time
NCT03258008 Recruiting Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer M.D. Anderson Cancer Center August 22, 2017
NCT03440567 Recruiting CCND1 Positive, CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, ransformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma City of Hope Medical Center February 21, 2018
NCT03318900 Recruiting Platinum Resistant Ovarian Cancer M.D. Anderson Cancer Center October 24, 2017
NCT03414658 Recruiting Breast Cancer Ian E. Krop, MD, PhD January 30, 2018
NCT03364348 Recruiting HER2 Positive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer George W. Sledge Jr. December 6, 2017
NCT03636503 Not yet recruiting Follicular Lymphoma Dana-Farber Cancer Institute August 17, 2018
NCT03390296 Recruiting Acute Myeloid Leukemia M.D. Anderson Cancer Center January 4, 2018
NCT02554812 Recruiting Advanced Cancer Pfizer September 18, 2015
NCT03217747 Recruiting Malignant Neoplasm of Breast, Malignant Neoplasms of Bone and Articular Cartilage, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasms of Respiratory and Intrathoracic Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract, Neoplasms of Uncertain or Unknown Behavior M.D. Anderson Cancer Center July 14, 2017
NCT03290937 Recruiting Malignant Neoplasms of Digestive Organs, Colorectal Cancer M.D. Anderson Cancer Center September 25, 2017
NCT02951156 Recruiting Diffuse Large B-Cell Lymphoma Pfizer November 1, 2016

What We Provide

Therapeutic Antibody
Utomilumab

We provide high-quality Utomilumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Reference
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?term=utomilumab


For research use only. Not intended for any clinical use.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare